Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks

Page 3 of 15

13. Zai Lab Limited (NASDAQ:ZLAB)

Number of Hedge Fund Holders: 18

Viking Global’s Stake: $47 million 

Zai Lab Limited (NASDAQ:ZLAB) is a commercial-stage biopharmaceutical company based in China and the US focused on bringing transformative medicines. The following aspects make the company an attractive prospect for investors. Firstly, the report for the third quarter showed great results, which may boost investors’ confidence in the company. For instance, the product revenue net was $101.8 million in the third quarter of 2024, compared to $69.2 million for the same period in 2023, representing 47% year-on-year growth. This increase was primarily driven by increased sales for VYVGART and was also supported by increased sales for ZEJULA and NUZYRA. In addition, research and development expenses were $66 million in the third quarter of 2024, compared to $58.8 million for the same period in 2023. This increase was primarily due to increased upfront and milestone fees for license and collaboration agreements. Secondly, Schrödinger and Zai Lab have announced a global R&D collaboration in Oncology, focused on a novel program in oncology targeting DNA damage response. This program may complement existing discovery efforts in the DNA damage response pathway in addition to potential combinatorial approaches within the pipeline, such as with the PARP inhibitor Zejula.

Page 3 of 15